Longeveron (LGVN) Non-Current Assets (2021 - 2026)
Longeveron's (LGVN) quarterly Non-Current Assets came in at $4.4 million in Q1 2026, down 21.86% year-on-year from $5.6 million in Q1 2025, and down 9.46% quarter-over-quarter from $4.8 million in Q4 2025.
Longeveron (LGVN) Non-Current Assets (2021 - 2026) Analysis & Trends
Longeveron's Non-Current Assets history runs 6 years deep, the most recent figure standing at $4.4 million for Q1 2026.
- On a quarterly basis, Non-Current Assets fell 21.86% year-over-year to $4.4 million in Q1 2026; TTM through Mar 2026 was $19.9 million, a 15.95% decrease from a year earlier, with the FY2025 full-year figure at $4.8 million, down 18.94% from the prior year.
- Non-Current Assets eased to $4.4 million in Q1 2026 per LGVN's latest filing, from $4.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $7.1 million in Q4 2022 and bottomed at $4.4 million in Q1 2026.
- The 5-year median for Non-Current Assets is $6.0 million (2024), against an average of $5.9 million.
- Across the five-year window, Non-Current Assets slipped 3.43% in 2022 and fell 21.86% in 2026, its largest moves.
- Year by year, Non-Current Assets stood at $7.1 million in 2022, then dropped by 12.66% to $6.2 million in 2023, then dropped by 4.75% to $5.9 million in 2024, then dropped by 18.94% to $4.8 million in 2025, then slipped by 9.46% to $4.4 million in 2026.
- Per Business Quant, the three latest LGVN Non-Current Assets figures stand at $4.4 million (Q1 2026), $4.8 million (Q4 2025), and $5.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | 4.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.36 Mn |
| Dec 31, 2025 | 4.81 Mn |
| Sep 30, 2025 | 5.22 Mn |
| Jun 30, 2025 | 5.48 Mn |
| Mar 31, 2025 | 5.57 Mn |
| Dec 31, 2024 | 5.93 Mn |
| Sep 30, 2024 | 6.14 Mn |
| Jun 30, 2024 | 5.98 Mn |
| Mar 31, 2024 | 5.94 Mn |
| Dec 31, 2023 | 6.23 Mn |
| Sep 30, 2023 | 6.58 Mn |
| Jun 30, 2023 | 6.80 Mn |
| Mar 31, 2023 | 6.94 Mn |
| Dec 31, 2022 | 7.13 Mn |
| Dec 31, 2021 | 7.39 Mn |